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1. Introduction 
Chlamydiae are small gram-negative obligate intracellular microorganisms that preferentially 
infect squamocolumnar epithelial cells. Chlamydia species which can cause infections in 
humans are C. pneumoniae, C. psittaci and C. trachomatis. Of the three species, C. trachomatis is 
responsible for sexually transmitted diseases (STDs) in men and women. Identified in 1907, 
C. trachomatis was the first chlamydial agent discovered in humans. The life cycle of C. 
trachomatis consists of an extracellular form (the elementary body) and the intracellular form 
(the reticulate body). The elementary body attaches to and penetrates columnar epithelial 
cells, where it transforms into the reticulate body, the active reproductive form of the 
organism. The reticulate body forms large inclusions within cells and then begins to 
reorganize into small elementary bodies. C. trachomatis can be differentiated into 18 serovars 
(serologically variant strains) based on monoclonal antibody–based typing assays. Serovars 
A, B, Ba, and C are associated with trachoma (a serious eye disease that can lead to 
blindness), serovars D-K are associated with genital tract infections, and L1-L3 are 
associated with lymphogranuloma venereum.  
The pathophysiologic mechanisms of chlamydiae are poorly understood. The initial response 
to infected epithelial cells is a neutrophilic infiltration followed by lymphocytes, 
macrophages, plasma cells, and eosinophilic invasion. The release of cytokines and 
interferons by the infected epithelial cell initializes this inflammatory cascade. Infection with 
chlamydial organisms invokes a humoral cell response, resulting in secretory 
immunoglobulin A (IgA) and circulatory immunoglobulin M (IgM) and immunoglobulin G 
(IgG) antibodies and a cellular immune response.  
C. trachomatis infections are prevalent worldwide, but current research, screening, and 
treatment are focused on females, with the burden of disease and infertility sequel 
considered to be a predominantly female problem. C. trachomatis is responsible for a wide 
spectrum of diseases that include vaginitis, cervicitis, salpingitis, endometritis, 
conjunctivitis, and neonatal pneumonia. A role for this pathogen in the development of 
male urethritis, epididymitis, and orchitis is widely accepted. Also, C. trachomatis can cause 
chronic prostatitis and infertility.  
This chapter covers C. trachomatis infection in urologic diseases focusing on male problems 
such as urethritis, epididymitis and orchitis; chronic prostatitis and infertility in terms of the 
epidemiology, screening, clinical manifestations, diagnosis, treatment and complication.  
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2. Epidemiology of C. trachomatis 
In contrast to gonorrhea infection, most men and women who are infected are 
asymptomatic, and, therefore, diagnosis is delayed until a positive screening result or 
upon discovering a symptomatic partner. Chlamydia has been isolated in approximately 
40-60% of males presenting with nongonococcal urethritis. Recent epidemiological studies 
indicate a high prevalence rate of asymptomatic men who act as a reservoir for 
chlamydial infections.  
Chlamydia is the most common bacterial sexually transmitted infection in the world, causing 
an estimated 89 million new cases of infection each year (World Health Organization 
[WHO], 2001). Ethnic group or socioeconomic deprivation, introducing a screening program 
that is less available and accessible, and less acceptable to people from vulnerable and 
disadvantaged groups, could create or widen existing inequalities in chlamydia prevalence. 
According to the Centers for Disease Control and Prevention, the last 5 years have seen an 
increasing rate of infection (43.5%) and it is more common in women than in men (3:1) in 
USA (Centers for Disease Control and Prevention [CDC], 2010).   
According to Low and colleagues (Low et al., 2007), in UK in 2004, 104,155 cases of chlamydia 
were diagnosed in genitourinary medicine clinics. The number of diagnosed infections has 
been increasing steadily since 1995, partly owing to increased numbers of people being 
tested; nearly 700,000 genital infections and sexually transmitted infections were diagnosed 
in genitourinary clinics in 2003 compared with 442,000 in 1995. In 2007, National Chlamydia 
Screening Programme was conducted with 4731 men and women aged 16–39 years 
participated in the cross-sectional screening survey in UK. There were 219 people with 
positive chlamydia results. Prevalence in 16–24-year-olds was 6.2% in women and 5.3% in 
men. The prevalence in young men was the same as in young women. The examination of 
risk factors for chlamydia in the prevalence and case–control studies did not find any factors, 
other than young age. The number of new partners in the past 12 months was the strongest 
predictor of infection.  
Population based studies in Europe and the USA suggest that the prevalence of chlamydia in 
men and women aged 15–24 years is 2–6% (Andersen et al., 2002; Fenton et al., 2001; Miller 
et al., 2004; van Bergen et al., 2005). The peak age group for infection is 16–19 years in 
women and 20–24 years in men (CDC, 2010).  
3. Screening  
Asymptomatic chlamydial infection is common among both men and women, and 
detection often relies on screening. Routine laboratory screening for common STDs is 
indicated for sexually active adolescents. The CDC and the US Preventive Services Task 
Force each recommend annual chlamydial screening for all sexually active women ≤ 25 
years of age and also for older women with risk factors (e.g., those who have a new sex 
partner or multiple sex partners). For the persons in correctional facilities, universal 
screening of adolescent females for chlamydia should be conducted at intake in juvenile 
detention or jail facilities. Universal screening of adult females should be conducted at 
intake among adult females up to 35 years of age or on the basis of local institutional 
prevalence data (CDC, 2010). 
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The benefits of screening could be demonstrated in areas where the prevalence of 
infection and rates of pelvic inflammatory diseases are decreasing since the screening 
programs began (Kamwendo et al., 1996; Scholes et al., 1996; Mertz et al., 1997; CDC, 
2010). Evidence is insufficient to recommend routine screening for C. trachomatis in 
sexually active young men based on feasibility, efficacy, and cost-effectiveness. However, 
screening of sexually active young men should be considered in clinical settings 
associated with high prevalence of chlamydia (e.g., adolescent clinics, correctional 
facilities, and STD clinics) (CDC, 2010).  
4. Clinical manifestation of chlamydial urethritis, epididymitis, prostatitis 
C. trachomatis is a bacterium whose sexually transmitted strains D–K cause genital tract 
infections in women (cervicitis and urethritis) and men (urethritis, epididymitis, prostatitis). 
However, chlamydia is known as a ‘silent’ disease because about three-quarters of infected 
women and about half of infected men have no symptoms (van de Laar & Morre, 2007).  
Symptoms of chlamydial urethritis, if present, include discharge of mucopurulent or 
purulent material, dysuria, urethral pruritis, urinary frequency or urgency, and show up 
about 1-3 weeks after being infected. One of the most common symptoms for in cases of 
chlamydia in men is a painful urination.  
In the worst cases chlamydia infection can, without treatment, lead on to other problems such 
as epididymitis or orchitis if the infection has made it to the epididymis or the testicles. This 
is particularly worrisome because it can occasionally cause a man to become sterile. In men 
younger than the age of 35 who are sexually active with women, the most common 
offending organisms causing epididymitis are N. gonorrhoeae and C. trachomatis. 
Approximately 45–85% of men with epididymitis have had prior C. trachomatis infections 
and/or gonococcal infections (Berger et al., 1978; Berger et al, 1979; Melekos & Asbach, 
1988). Acute epididymitis represents sudden occurrence of pain and swelling of the 
epididymis associated with acute inflammation of the epididymis. Physical examination 
localizes the tenderness to the epididymis (although in many cases the testis is also 
involved in the inflammatory process and subsequent pain—referred to as epididymo-
orchitis). The spermatic cord is usually tender and swollen. Early on in the process, only 
the tail of the epididymis is tender, but the inflammation quickly spreads to the rest of the 
epididymis and if it continues to the testis, the swollen epididymis becomes 
indistinguishable from the testis. Although the process is usually unilateral, it is 
sometimes bilateral. Physical examination may reveal a toxic and febrile patient. The skin 
of the involved hemiscrotum is erythematous and edematous, and the testis is quite 
tender to palpation or can be associated with a transilluminating hydrocele. If the 
diagnosis is not evident from the history, physical examination, and these simple tests, 
scrotal ultrasonography should be performed (to rule out malignancy in patients with 
chronic orchitis/orchialgia). The most important differential diagnosis in young men and 
boys is testicular torsion. Testicular torsion is often difficult to differentiate from an acute 
inflammatory condition. Scrotal ultrasound (with use of Doppler imaging to determine 
testicular blood flow) is especially helpful in differential diagnosis, but occasionally it will 
miss the diagnosis (particularly with intermittent or partial torsion) and the clinician 
should err in favor of the surgically correctable diagnosis of torsion. 
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Another potential problem without treatment of the chlamydia infection is chronic prostatitis.  
The evidence supporting the role of C. trachomatis in chronic prostatitis is conflicting. The 
predominant symptom of chronic prostatitis is pain, which is most commonly localized to 
the perineum, suprapubic area, and penis but can also occur in the testes, groin, or low back. 
Pain during or after ejaculation is one of the most prominent, important, and bothersome 
feature in many patients. Irritative and obstructive voiding symptoms including urgency, 
frequency, hesitancy, and poor interrupted flow are associated. Infertility and chronic 
prostatitis will be discussed in the ‘7. Complications’.  
The C. trachomatis strains L1, L2 and L3 cause lymphogranuloma venereum. This tropical 
sexually transmitted infection is currently responsible for outbreaks of ulcerative proctitis 
mainly affecting homosexual men (many with HIV infection) in various European countries 
and the USA (Blank et al., 2005; Nieuwenhuis et al., 2004; Nieuwenhuis et al., 2003). 
5. Diagnosis 
Detection of current chlamydia infection is based on demonstration of the organism. Tissue 
culture methods, direct fluorescent antibody tests or enzyme-linked immunosorbent assays 
(EIA) have now been largely replaced by nucleic acid amplification tests (NAATs). Culture 
and hybridization tests require urethral swab specimens, whereas NAATs can be performed 
on urine specimens. The sensitivity and specificity of the NAATs are clearly the highest of 
any of the test platforms for the diagnosis of chlamydial infections. Since accurate diagnosis 
is the goal, there is no justification for the ongoing use of other technologies. Non‐culture 
tests such as EIA and DNA probe assays are inferior to NAATs with respect to performance. 
According to the Expert Consultation Meeting Summary Report 2009, NAATs are 
recommended for detection of reproductive tract infections caused by C. trachomatis in men 
and women with and without symptoms.  
Optimal specimen types for NAATs are first catch urine from men and vaginal swabs from 
women. There is little need for urethral swab specimens and in some studies these samples 
are less sensitive than urine; urethral swab specimens and male urine were equivalent in 
specificity. For female screening, vaginal swab specimens are the preferred specimen type. 
Vaginal swab specimens are as sensitive as cervical swab specimens and there is no 
difference in specificity. Cervical samples are acceptable when pelvic examinations are 
done, but vaginal swab specimens are an appropriate sample type even when a full pelvic 
exam is being performed. Cervical sample specimens are certainly acceptable for NAAT 
testing in those settings that combine Pap and sexually transmitted infection testing from 
the same sample, such as liquid cytology. There was some concern about some liquid 
cytology samples being more likely to result in inhibition of amplification or contamination 
in some assays, as well as, a concern that liquid cytology samples lead to testing of 
populations at low risk for infection. Female urine, while acceptable, may have reduced 
performance when compared to genital swab samples. NAATs are also recommended for 
the detection of rectal and oropharyngeal infections caused by C. trachomatis. However, 
these specimen types have not been cleared by the FDA for use with NAATs and 
laboratories must establish performance specifications to satisfy CMS regulations for CLIA 
compliance prior to reporting results for patient management. Ninety five percent of testing 
for chlamydia performed using a test of choice or acceptable test (Table 1). 
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Test 
Sites 
FCU Cervix Urethra Pharynx Rectum 
Vulvo‐
vaginal 
NAAT 1 1 1 3 3 3 
EIA 4 2 2 5 5 5 
DFA 2 2 2 2 2 5 
TC 5 2 2 1 1 5 
FCU, First catch urine; NAAT, nucleic acid amplification test; EIA, enzyme immunoassay; DFA, direct 
fluorescent antibody; TC, tissue culture. 
1, test of choice; 2, acceptable, but not first choice; 3, not licensed, although encouraging work being 
performed; 4, only for use in asymptomatic males; 5, not recommended. 
All recommendations are at grade B unless stated otherwise. 
Table 1. Summary of recommended tests for use with different sites of samples (Carder et 
al., 2006) 
These tests are very accurate, but are laboratory dependent, creating a delay between 
testing and receipt of diagnosis, caused by the time it takes to transport the test sample to 
the laboratory and process the result. This delay is problematic, as a number of infected 
patients will not return for treatment, following their positive diagnosis. Point-of-care 
testing methods can provide results within hours after the tests are carried out, which 
could allow infected patients to be treated immediately, as well as allowing the immediate 
identification of recent sexual partners who should also be tested. The Chlamydia Rapid 
Test is a point-of-care test that has reported improved accuracy. However, according to 
the recent systematic review of the clinical effectiveness and cost-effectiveness of rapid 
point-of-care tests for the detection of genital chlamydia infection, NAATs was found to be 
less costly and more effective, although there were circumstances under which point-of-
care testing could become a viable alternative (i.e. if uptake rates for testing were 
increased using this point-of-care method) (Hislop et al., 2010). There are currently no 
point‐of‐care assays on the market that are suitable for routine use, although some may be 
of use in high risk populations where immediate treatment is the overriding concern due 
to poor follow up. The group felt that development of improved point-of-care tests 
desirable.  
Laboratory tests should include Gram stains of a urethral smear and a midstream urine 
specimen. A urethral swab and midstream urine specimen should be sent for culture and 
sensitivity testing. When a boy or young man is diagnosed with epididymitis or orchitis, 
and the diagnosis is uncertain, he should be further evaluated with duplex Doppler scrotal 
ultrasonography to rule out torsion.  
To detect recent or past exposure to C. trachomatis, both systemic and local antibodies in 
secretions can be used. In order to be considered as a diagnostic test the specificity must be 
high. The microimmunofluorescence test is considered the gold standard but is difficult to 
perform and the specificity of the test has been questioned. Antibodies to the chlamydial 
lipopolysaccharide could cause cross-reactivity but specific antibodies to C. pneumoniae and 
C. trachomatis can usually be distinguished by the test. ELISA tests based on peptides from 
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the major outer-membrane protein polyantigen of C. trachomatis have so far showed high 
specificities. Although IgG antibodies can be detected in serum in 40-100% of infected 
women, demonstrated by cell culture or NAAT, 16-87% of C. trachomatis-negative women 
also have such antibodies. The situation is similar for serum IgA antibodies but at a lower 
level. The predictive values therefore become unacceptably low to use IgG or IgA antibodies 
in serum to diagnose current lower genital tract infection. The shorter half-life of IgA 
antibodies compared to IgG has suggested that IgA antibodies could reflect persistent 
infection. There is no solid ground as yet for the use of IgA antibodies as a marker of 
persistent or unresolved infection by C. trachomatis. IgM antibodies may have a better 
positive predictive value but the sensitivity is too low, which precludes their use for the 
diagnosis of genital chlamydial infection (Persson, 2002).  
6. Treatment  
Uncomplicated lower genital tract chlamydia infections can be cured by a single dose or short 
course of antibiotics. The guidelines for the treatment of persons who have or are at risk for 
STDs were updated by CDC after consultation with a group of professionals knowledgeable 
in the field of STDs who met in Atlanta on April 18–30, 2009. The approach to the 
management of uncomplicated genital chlamydial infection in adults includes (1) treatment 
of patients (to reduce complications and prevent transmission to sex partners), (2) treatment 
of sex partners (to prevent reinfection of the index patient and infection of other partners), 
(3) risk-reduction counseling, and (4) repeat chlamydial testing in women a few months 
after treatment (to identify recurrent/persistent infections). In the guidelines, the CDC 
convened an advisory group to examine recent abstracts and published literature 
addressing management of C. trachomatis infections in adolescents and adults. Key 
questions were posed and answered on the basis of quality of evidence and expert 
opinion. Clinical trials continue to demonstrate equivalent efficacy and tolerability of 
azithromycin and doxycycline regimens, and both remain recommended as first-line 
therapy in nonpregnant individuals. Azithromycin 1g and doxycycline 100mgs bd for 7 
days have been shown to be >95% effective in the treatment of uncomplicated lower 
genital tract C. trachomatis infection (Horner, 2008; Horner & Boag, 2006). For those with 
upper genital tract disease i.e., pelvic inflammatory disease, a prolonged course of 
treatment for up to 14 days is recommended (Royal College of Obstetricians and 
Gynaecologists [RCOG], 2008). More data and clinical experience are available to support 
the efficacy, safety, and tolerability of azithromycin in pregnant women. Evidence is 
building that expedited partner therapy, with provision of treatment or a prescription, 
may be just as effective as or more effective than standard partner referral in ensuring 
partner treatment and preventing chlamydia recurrence in women. Although there are 
more studies needed and barriers to be addressed before its widespread use, expedited 
partner therapy will be recommended as an option for partner management.  
Test of cure is not routinely recommended if standard treatment has been given, there is 
confirmation that the patient has adhered to therapy, and there is no risk of re‐infection. 
However, if these criteria cannot be met or if the patient is pregnant a test of cure is advised. 
This should be taken using the same technique as was used for the initial testing. Ideally, a 
minimum of 3–5 weeks post‐treatment is required as NAATs will demonstrate residual 
DNA/RNA even after successful treatment of the organism (recommendation grade A). 
www.intechopen.com
 
Chlamydial Infection in Urologic Diseases 275 
7. Complications 
C. trachomatis can cause damage to both women and men’s reproductive organs. If chlamydia 
is left untreated, men may develop chronic complications or irreversible damage which may 
cause male infertility. There is not thought to be any lasting immunity following a chlamydia 
infection that has resolved spontaneously or been treated with antibiotics, so repeated 
infections can occur (Holmes et al., 1999).  
7.1 Chronic prostatitis 
Prostatitis is the most common urologic diagnosis in men younger than 50 years and 
represents 8% of urology office visits (Collins et al., 1998). Chronic pelvic pain syndrome 
(CPPS) which is divided into two categories, inflammatory CPPS (Category ⅢA which 
corresponds to the former chronic nonbacterial prostatitis), and non-inflammatory CPPS 
(Category ⅢB which corresponds to the former prostatodynia), is the most common type of 
prostatitis. It is condition that many clinicians find difficult to treat effectively. The problem 
is that although in semen and expressed prostatic secretions there is evidence of 
inflammation, no pathogens are usually found in samples analyzed when routine culture 
methods are used. The clinical symptoms of patients with CPPS IIIA and IIIB are similar, 
perineal pain, often radiating to the genital area, urinary symptoms, ejaculatory disturbance, 
and are of chronic nature. The cause of CPPS has not yet been established and there is a lot 
of controversy regarding its etiology (Motrich et al., 2005). However, there is some 
substantial empirical support for a potential role of genitourinary tract infections in chronic 
prostatitis/CPPS as the etiology of this disease. Many patients relate the onset to sexual 
activity, often to an episode of urethritis (Krieger et al., 1999).  Antimicrobials often provide 
transient or partial relief of symptoms and standard practice is to provide multiple courses 
of antimicrobials (Nickel et al., 1994; Nickel & Costerton, 1992). For many years attempts 
have been made to prove the role of certain microorganisms in the pathogenesis of CPPS. 
Attention has focused on C. trachomatis, the most frequent cause of non-gonococcal urethritis 
in sexually active men. It is believed that these bacteria can spread via intracanalicular 
ascension from the urethra. However, the evidence supporting the role of C. trachomatis as 
an etiologic agent in chronic prostatitis is conflicting. Mardh and Colleen (Mardh et al., 
1972) found that one third of men with chronic prostatitis had antibodies to C. trachomatis 
compared with 3% of controls. Shortliffe and coworkers (Shortliffe et al., 1992) found that 
20% of patients with nonbacterial prostatitis had antichlamydial antibody titers in the 
prostatic fluid. Bruce and colleagues (Bruce et al., 1981) found that 56% of patients with 
“subacute or chronic prostatitis” were infected with C. trachomatis (examining early morning 
urine, prostatic fluid, or semen). In a follow-up study, Bruce and Reid (Bruce & Reid, 1989) 
found that 6 of 55 men with abacterial prostatitis, including 31 believed to have chlamydial 
prostatitis, met strict criteria for positive diagnosis for chlamydial prostatitis based on 
identification of the organisms by culturing or immunofluorescence. Chlamydia has also been 
isolated in prostate tissue specimens. Poletti and coworkers (Poletti et al., 1985) isolated C. 
trachomatis from prostate samples obtained by transrectal aspiration biopsy of men with 
“nonacute abacterial prostatitis.” Abdelatif and colleagues (Abdelatif et al., 1991) identified 
intracellular chlamydia employing “in-situ hybridization techniques” in transurethral 
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prostate chips from 30% of men with histologic evidence of “chronic abacterial prostatitis.” 
Shurbaji and associates (Shurbaji et al., 1988) identified C. trachomatis in paraffin-embedded 
secretions in 31% of men with histologic evidence of prostatitis compared with none in 
patients with BPH without inflammation. 
Although Mardh and Colleen (Mardh et al., 1972) suggested that C. trachomatis may be 
implicated in as many as one third of men with CP, their follow-up studies employing 
culturing and serologic tests could not confirm C. trachomatis as an etiologic agent in 
idiopathic prostatitis (Mardh & Colleen, 1975; Mardh et al., 1978). Shortliffe and Wehner 
(Shortliffe & Wehner, 1986) came to a similar conclusion when they evaluated 
antichlamydial antibody titers in prostatic fluid. Twelve percent of controls compared 
with 20% of patients with nonbacterial prostatitis had detectable antibodies. Berger and 
coworkers (Berger et al., 1989) could not culture C. trachomatis from the urethras in men 
with CP nor did they find a serologic or local immune response to C. trachomatis in such 
patients. Doble and associates (Doble et al., 1989) were not able to culture or detect by 
immunofluorescence chlamydia in transperineal biopsies of abnormal areas of the prostate 
in men with chronic abacterial prostatitis. Krieger and colleagues (Krieger et al., 1996) 
were only able to find chlamydia in 1% of prostate tissue biopsies in men with CP. A 
further localization and culture series by Krieger and associates (Krieger et al., 2000) also 
failed to culture chlamydia from either urethral or prostate specimens. Further elucidation 
of the role of chlamydial etiology of prostate infection is required to make any definitive 
statement on the association between isolation of this organism and its prostatic origin 
and effect (Weidner et al., 2002). In the follow-up of standardized prostatitis patients, a 
combination of urological tests in EPS and seminal plasma combined with genital 
chlamydial DNA material, may further elucidate the chlamydial aetiology of prostate 
infection. 
7.2 Infertility 
There are some studies of C. trachomatis in men and women undergoing investigations for 
infertility using modern screening methods. The major sequelae of C. trachomatis infection in 
women are tubal factor infertility and tubal ectopic pregnancy. Sequelae of C. trachomatis 
infection in men may include male factor infertility but why this occurs remains uncertain . 
There have been a number of studies on the relationship between C. trachomatis infection 
and sperm quality, with conflicting results. However, there have been major differences in 
study design with: significant variation in the methodology used to measuring the history of 
chlamydial infection (i.e. serology versus molecular methods); as well as variable and 
sometimes inadequate methods to assess semen quality. More recent studies (Hosseinzadeh 
et al., 2004; Bezold et al., 2007; Al-Mously et al., 2009), using molecular methods to detect 
infection, and robust methods of laboratory andrology to examine semen, have generally 
found that men with a current infection of C. trachomatis have poorer quality ejaculates 
compared than men who do not. It is unclear whether this is because of reduced levels of 
spermatogenesis in the presence of the bacterium, or whether infection causes an altered 
ejaculatory response. However, it has been observed that persistent infection can result in 
the scarring of ejaculatory ducts or loss of stereocilia (Gonzalez-Jimenez & Villanueva-Diaz, 
2006). In addition to any changes in semen quality, there is growing evidence to suggest that 
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exposure to C. trachomatis can affect sperm function (Pacey & Eley, 2004; Eley et al., 2005a). 
In vitro experiments have shown that C. trachomatis triggers tyrosine phosphorylation of 
sperm proteins (Hosseinzadeh et al., 2000), induces premature sperm death (Hosseinzadeh 
et al., 2001) and stimulates an apoptosis-like response in sperm (Eley et al., 2005b; Satta et 
al., 2006), leading to increased levels of sperm DNA fragmentation (Gallegos et al., 2008; 
Satta et al., 2006). At least some of these effects are caused by lipopolysaccharides 
(Hosseinzadeh et al., 2003).  
With regard to infertility patients receiving treatments such as IVF, the Royal College of 
Obstetricians and Gynaecologists recommended that women should be screened for C. 
trachomatis, or given appropriate antibiotic prophylaxis, before any uterine instrumentation 
takes place (RCOG, 2008). This was reiterated in the later NICE guidelines (UK 
Collaborative Group for HIV and STI Surveillance, 2005). However, Sowerby and Parsons 
(Sowerby & Parsons, 2004) noted that 53% of UK clinics either screen the female partner or 
give appropriate antibiotic prophylaxis. In the recruitment of sperm, egg and embryo 
donors the most recent UK guidelines produced by the Association of Biomedical 
Andrologists, Association of Clinical Embryologists, British Andrology Society, British 
Fertility Society and Royal College of Obstetricians and Gynaecologists (RCOG, 2008) 
recommend that all donors be screened for C. trachomatis prior to donation, and this is 
reiterated in the 8th Edition of the Human Fertilisation and Embryology Authority (HFEA) 
Code of Practice (HFEA Code of Practice, 2009). 
Since it is known C. trachomatis can survive in liquid nitrogen (Sherman & Jordan, 1985) 
and that infection following insemination with cryopreserved donor semen is possible 
(Broder et al., 2007), the freezing and storage of gametes and embryos from patients with 
an active C. trachomatis infection is of obvious concern. This is not only to prevent women 
who receive treatment with thawed gametes and embryos from becoming infected with C. 
trachomatis, but because of the theoretical concern that the bacteria may cross-contaminate 
other (C. trachomatis negative) samples being stored in the same cryostorage vessel. To 
date, such cross contamination has only been shown with regard to Hepatitis B during 
storage of peripheral blood stem cells. (Tedder et al., 1995) and has never been 
demonstrated during reproductive tissue storage. However, the HFEA now require that 
all patients placing material in storage be screened for bloodborn viruses prior to placing 
material in storage (HFEA Code of Practice, 2009). For patients undergoing planned IVF 
treatment, a similar level of risk reduction will be achieved if both partners are screened 
and treated for C. trachomatis. 
8. Conclusion 
Population based studies in Europe and the USA suggest that the prevalence of C. 
trachomatis in men and women aged 15–24 years is 2–6%. The prevalence in young men was 
the same as in young women.The peak age group for infection is 16–19 years in women and 
20–24 years in men. A role for C. trachomatis in the development of male urologic diseases 
such as urethritis, epididymitis, and orchitis is widely accepted. Also, C. trachomatis can 
cause chronic prostatitis and infertility. NAATs are recommended for detection of 
reproductive tract infections caused by C. trachomatis in men and women. Optimal specimen 
types for NAATs are first catch urine from men and vaginal swabs from women. Clinical 
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trials continue to demonstrate equivalent efficacy and tolerability of azithromycin and 
doxycycline regimens, and both remain recommended as first-line therapy. Ascending 
chlamydial infections have been thought to be an infective cause of prostatitis. 
Unfortunately, the definitive association between C. trachomatis and prostatitis is limited by 
various factors. Sequelae of C. trachomatis infection in men may include male factor 
infertility but why this remains uncertain.  
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